Self‐reported distress · children aged 2‐19 years with mixed medical (acute or chronic illness) or generally healthy undergoing venipuncture, immunization,…
1 finding from 1 review
Self‐reported distress · children aged 3‐12 years with mixed medical (acute or chronic illness) or unclear diagnoses undergoing venipuncture or intravenous insertion
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Observer‐reported pain · children aged 3‐12 years with mixed medical (acute or chronic illness) or unclear diagnoses undergoing venipuncture or intravenous insertion
1 finding from 1 review
Observer‐reported distress · children aged 3‐12 years with mixed medical (acute or chronic illness) or unclear diagnoses undergoing venipuncture or intravenous insertion
1 finding from 1 review
Behavioral measures‐ pain · children aged 3‐12 years with mixed medical (acute or chronic illness) or unclear diagnoses undergoing venipuncture or intravenous insertion
1 finding from 1 review
Behavioral measures‐ distress · children aged 3‐12 years with mixed medical (acute or chronic illness) or unclear diagnoses undergoing venipuncture or intravenous insertion
1 finding from 1 review
Observer‐reported pain · children aged 2‐19 years with mixed medical (acute or chronic illness) or generally healthy undergoing venipuncture, immunization,…
1 finding from 1 review
Observer‐reported distress · children aged 2‐19 years with mixed medical (acute or chronic illness) or generally healthy undergoing venipuncture, immunization,…
1 finding from 1 review
Behavioral measures‐ pain · children aged 2‐19 years with mixed medical (acute or chronic illness) or generally healthy undergoing venipuncture, immunization,…
1 finding from 1 review
Behavioral measures‐ distress · children aged 2‐19 years with mixed medical (acute or chronic illness) or generally healthy undergoing venipuncture, immunization,…
1 finding from 1 review
Self‐reported pain · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review
Self‐reported distress · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review
Observer‐reported pain · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review
Proportion of participants reporting no worse than mild pain by 14 days after start of treatment · adults with cancer‐related pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change much or very much improved · adults with cancer‐related pain
Cannabis‐based medicines probably leads to higher PGIC of much improved or very much improved compared with placebo medication (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in withdrawals due to adverse events compared with placebo medication (moderate certainty).
1 finding from 1 review
Mean pain intensity (Numeric Rating Scale 0–10) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in mean pain intensity (Numeric Rating Scale 0–10) compared with placebo medication (moderate certainty).
1 finding from 1 review
Daily maintenance opioid dosage (mg morphine equivalent) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in daily maintenance opioid dosage (mg morphine equivalent) compared with placebo medication (low certainty).
1 finding from 1 review
Daily breakthrough opioid dosage (mg morphine equivalent) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in daily breakthrough opioid dosage (mg morphine equivalent) compared with placebo medication (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in participants experiencing any serious adverse event compared with placebo medication (moderate certainty).
1 finding from 1 review